Second opinions improve adhd prescribing in a medicaid-insured community population

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 48, Issue 7, 2009, Pages 740-748

  Thompson, Jeffery N ^a,c   Varley, Christopher K ^b   McClellan, Jon ^b   Hilt, Robert ^b   Lee, Terry ^b   Kwan, Alan C ^a   Lee, Taik ^a   Trupin, Eric ^b  

^a Health Services   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NONE   (United States)

Author keywords

ADHD; Previous authorization; Second opinions

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METADATA; METHYLPHENIDATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COMMUNITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL FEE; NURSE PRACTITIONER; PHYSICIAN; PHYSICIAN ASSISTANT; POPULATION; PRESCHOOL CHILD; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHIATRIST; SCHOOL CHILD; TREATMENT WITHDRAWAL; UNITED STATES;

EID: 68749083408     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1097/CHI.0b013e3181a2b2ed     Document Type: Article

References (33)

1. Mayes R, Bagwell C, Erkulwater J. ADHD and the rise in stimulant use among children. Harv Rev Psychiatry. 2008;16:151-166.
2. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry. 2006;163:579-585.
3. Brown RT, Amler RW, Freeman WS et al. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115:e749-757.
4. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA. 1998;279:1100-1107.
5. Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:975-984; discussion 984-994.
6. Foy JM, Earls MF. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder. Pediatrics. 2005;115:e97-e104.
7. Bernfort L, Nordfeldt S, Persson J. ADHD from a socio-economic perspective. Acta Paediatr. 2008;97:239-245.
8. Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML. Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm. 2007;13(9 Suppl B):S2-S13; quiz S14-S16.
9. Thomas C, Hypponen E, Power C. Obesity and type 2 diabetes risk in midadult life: the role of childhood adversity. Pediatrics. 2008;121: e1240-e1249.
10. Kessler RC, Adler L, Barkley R et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
11. Pelham WE, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:E105.
12. Sung V, Hiscock H, Sciberras E, Efron D. Sleep problems in children with attention-deficit/hyperactivity disorder: prevalence and the effect on the child and family. Arch Pediatr Adolesc Med. 2008;162:336-342.
13. Reiersen AM, Todd RD. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. Expert Rev Neurother. 2008;8:657-669.
14. Schneider H, Eisenberg D. Who receives a diagnosis of attention-deficit/hyperactivity disorder in the United States elementary school population? Pediatrics. 2006;117:e601-e609.
15. Jadad AR, Booker L, Gauld M et al. The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses. Can J Psychiatry. 1999;44:1025-1035.
16. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475-1488.
17. McDonagh M, Peterson KS, Dana T, Thakurta S. Drug Class Review on Pharmacologic Treatments for ADHD Final Report. Portland: Oregon Health and Science University; 2007.
18. King S, Griffin S, Hodges Z et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006;10:iii-iv, xiii-146.
19. Vitiello B. Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics. 2001;108:983-989.
20. Spetie L, Arnold LE. Ethical issues in child psychopharmacology research and practice: emphasis on preschoolers. Psychopharmacology (Berl). 2007;191:15-26.
21. Vandereycken W. [Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry]. Tijdschr Psychiatr. 2006;48: 119-129.
22. Services TDoSH. Psychotropic Medication Utilization Parameters for Foster Children. Version 061221. http://www.dshs.state.tx.us/mhprograms/pdf/ PsychotropicMedicationUtilizationParametersFosterChildren.pdf. Accessed Aug 17, 2008.
23. Representatives Dickerson, Kagi, Haler et al. AN ACT Relating to children's mental health services. Second Substitute House BilI 1088. 2007.
24. Senators Deccio, Thibaudeau, Winsley, Swecker, Franklin. Senate Bill 6088. 2005.
25. Senators Deccio, Thibaudeau, Winsley, Swecker, Franklin. Making prescription drugs more affordable to certain groups. Senate Bill 6088, Washington state; 2003.
26. Washington Prescription Drug Program. http://www.rx.wa.gov/. Accessed December 30, 2008.
27. Cox ER, Motheral BR, Henderson RR, Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics. 2003;111:237-243.
28. Bruns EJ, Hoagwood KE, Rivard JC, Wotring J, Marsenich L, Carter B. State implementation of evidence-based practice for youths, part II: recommendations for research and policy. J Am Acad Child Adolesc Psychiatry. 2008;47:499-504.
29. Bruns EJ, Hoagwood KE. State implementation of evidence-based practice for youths, Part I: responses to the state of the evidence. JAm Acad Child Adolesc Psychiatry. 2008;47:369-373.
30. Harpaz-Rotem I, Rosenheck RA. Prescribing practices of psychiatrists and primary care physicians caring for children with mental illness. Child Care Health Dev. 2006;32:225-237.
31. Kuhlthau K, Nyman RM, Ferris TG, Beal AC, Perrin JM. Correlates of use of specialty care. Pediatrics. 2004;113(3 Pt 1):e249-e255.
32. Rushton JL, Fant KE, Clark SJ. Use of practice guidelines in the primary care of children with attention-deficit/hyperactivity disorder. Pediatrics. 2004;114:e23-e28.
33. Representatives Dickerson, Kagi, Haler et al. Improving delivery of children's mental health services. House Bill 1088. Vol. RCW 71.36.005, Washington state; 2007.